Eli Lilly and Co. said Tuesday it is planning to add two more cheaper versions of its insulin product Humalog starting in mid-April. The drug company said its Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will have list prices that are 50% lower than branded versions. The company first made a version of its lower-priced Insulin Lispro Injection available in May of last year at a 50% lower list price than Humlalog. More than 67,000 people filled prescriptions for that product in November of 2019 and another roughly 10% of people using Humalog transitioned to the lower-priced product. Lilly shares have gained 21% in the last 12 months, while the S&P 500 has gained 27%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.